S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NYSE:BIO

Bio-Rad Laboratories (BIO) Stock Forecast, Price & News

$522.20
-1.12 (-0.21%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$511.69
$534.75
50-Day Range
$475.22
$597.16
52-Week Range
$468.86
$832.70
Volume
217,556 shs
Average Volume
232,738 shs
Market Capitalization
$15.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.93
30 days | 90 days | 365 days | Advanced Chart
Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Bio-Rad Laboratories logo

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Headlines

Bio-Rad Laboratories (NYSE:BIO) Downgraded by TheStreet
Bio-Rad Reports First-Quarter 2022 Financial Results
See More Headlines

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
CUSIP
09057220
Employees
7,900
Year Founded
1952

Sales & Book Value

Annual Sales
$2.92 billion
Cash Flow
$16.40 per share
Book Value
$340.09 per share

Profitability

Net Income
$4.25 billion
Pretax Margin
-7.95%

Debt

Price-To-Earnings

Miscellaneous

Free Float
21,738,000
Market Cap
$15.64 billion
Optionable
Optionable

Company Calendar

Last Earnings
4/28/2022
Today
5/21/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.50 out of 5 stars

Medical Sector

139th out of 1,420 stocks

Analytical Instruments Industry

5th out of 32 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -













Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

Is Bio-Rad Laboratories a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bio-Rad Laboratories stock.
View analyst ratings for Bio-Rad Laboratories
or view top-rated stocks.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Bio-Rad Laboratories
.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) issued its quarterly earnings results on Thursday, April, 28th. The medical research company reported $4.94 earnings per share for the quarter, beating analysts' consensus estimates of $2.80 by $2.14. The medical research company had revenue of $700.10 million for the quarter, compared to the consensus estimate of $678 million. Bio-Rad Laboratories had a positive trailing twelve-month return on equity of 3.66% and a negative net margin of 3.49%. The business's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the previous year, the business earned $5.21 earnings per share.
View Bio-Rad Laboratories' earnings history
.

What guidance has Bio-Rad Laboratories issued on next quarter's earnings?

Bio-Rad Laboratories issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.92 billion-$2.95 billion, compared to the consensus revenue estimate of $2.91 billion.

What price target have analysts set for BIO?

3 Wall Street analysts have issued twelve-month target prices for Bio-Rad Laboratories' stock. Their forecasts range from $700.00 to $930.00. On average, they anticipate Bio-Rad Laboratories' stock price to reach $793.33 in the next year. This suggests a possible upside of 51.9% from the stock's current price.
View analysts' price targets for Bio-Rad Laboratories
or view top-rated stocks among Wall Street analysts.

Who are Bio-Rad Laboratories' key executives?
Bio-Rad Laboratories' management team includes the following people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 72, Pay $3.15M)
  • Mr. Ilan Daskal, Exec. VP & CFO (Age 56, Pay $1.18M) (LinkedIn Profile)
  • Dr. Andrew J. Last, Exec. VP & COO (Age 62, Pay $1.54M)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 60, Pay $974.94k) (LinkedIn Profile)
  • Ms. Dara Grantham Wright, Exec. VP & Pres of Clinical Diagnostics Group (Age 46, Pay $1.06M)
  • Mr. Ajit Ramalingam, Sr. VP & Chief Accounting Officer (Age 49)
  • Diane Dahowski, Sr. VP of Global Technology & Systems
  • Mr. Yong Chung, VP of Investor Relations
  • Mr. Timothy S. Ernst, Exec. VP, Gen. Counsel & Sec. (Age 62) (LinkedIn Profile)
  • Colleen Corey, Sr. VP of Global HR
What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?

325 employees have rated Bio-Rad Laboratories CEO Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among Bio-Rad Laboratories' employees.

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.74%), BlackRock Inc. (5.88%), State Street Corp (3.29%), Brown Advisory Inc. (1.94%), Acadian Asset Management LLC (1.39%) and Invesco Ltd. (1.18%). Company insiders that own Bio-Rad Laboratories stock include Annette Tumolo, Giovanni Magni, Ilan Daskal, Michael Crowley and Timothy S Ernst.
View institutional ownership trends for Bio-Rad Laboratories
.

Which institutional investors are selling Bio-Rad Laboratories stock?

BIO stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Artemis Investment Management LLP, National Pension Service, KBC Group NV, GW&K Investment Management LLC, State Street Corp, Rhumbline Advisers, and Russell Investments Group Ltd.. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Annette Tumolo, Ilan Daskal, Michael Crowley, and Timothy S Ernst.
View insider buying and selling activity for Bio-Rad Laboratories
or view top insider-selling stocks.

Which institutional investors are buying Bio-Rad Laboratories stock?

BIO stock was acquired by a variety of institutional investors in the last quarter, including Polar Asset Management Partners Inc., Prudential Financial Inc., Brown Advisory Inc., Invesco Ltd., Easterly Investment Partners LLC, Bellevue Group AG, Vanguard Group Inc., and Virginia Retirement Systems ET AL.
View insider buying and selling activity for Bio-Rad Laboratories
or or view top insider-buying stocks.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $522.20.

How much money does Bio-Rad Laboratories make?

Bio-Rad Laboratories has a market capitalization of $15.64 billion and generates $2.92 billion in revenue each year. The medical research company earns $4.25 billion in net income (profit) each year or ($4.88) on an earnings per share basis.

How many employees does Bio-Rad Laboratories have?

Bio-Rad Laboratories employs 7,900 workers across the globe.

Does Bio-Rad Laboratories have any subsidiaries?

The following companies are subsidiares of Bio-Rad Laboratories: (f/k/a Bio-Rad Laboratories (Israel) Inc.), BIO-RAD spol. s r.o., Bio-Metrics (U.K.) Limited, Bio-Rad, Bio-Rad (Shanghai) Life Science Research & Development Co. Ltd., Bio-Rad 1, Bio-Rad AbD Serotec GmbH, Bio-Rad AbD Serotec Ltd, Bio-Rad China Ltd., Bio-Rad Denmark ApS, Bio-Rad Europe GmbH, Bio-Rad Export LLC, Bio-Rad Finland Oy (f/k/a DiaMed Fennica Oy), Bio-Rad France, Bio-Rad France Holding, Bio-Rad Germany Holding GmbH, Bio-Rad Haifa Ltd., Bio-Rad Holdings LLC, Bio-Rad Hungary Trading LLC, Bio-Rad IHC Europe GmbH, Bio-Rad Innovations, Bio-Rad Korea Ltd., Bio-Rad Laboratories (Canada) Limited, Bio-Rad Laboratories (India) Private Limited, Bio-Rad Laboratories (Pty) Ltd, Bio-Rad Laboratories (Rishon) Inc., Bio-Rad Laboratories (Shanghai) Co. Ltd., Bio-Rad Laboratories (Singapore) Pte Ltd, Bio-Rad Laboratories AB, Bio-Rad Laboratories AG, Bio-Rad Laboratories B.V., Bio-Rad Laboratories Ges.m.b.H., Bio-Rad Laboratories GmbH, Bio-Rad Laboratories K.K., Bio-Rad Laboratories Limited, Bio-Rad Laboratories Logistik GmbH, Bio-Rad Laboratories Ltd., Bio-Rad Laboratories M.EPE, Bio-Rad Laboratories NV, Bio-Rad Laboratories Pty Ltd, Bio-Rad Laboratories S.A., Bio-Rad Laboratories S.r.l., Bio-Rad Laboratories SAS, Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios Lda, Bio-Rad Laboratorii OOO, Bio-Rad Laboratórios Brasil Ltda., Bio-Rad Luxembourg S.à r.l., Bio-Rad Medical Diagnostics GmbH, Bio-Rad Middle East FZ-LLC, Bio-Rad Norway AS, Bio-Rad Pacific Limited, Bio-Rad Pasteur, Bio-Rad Polska Sp. z o.o., Bio-Rad QL Inc., Bio-Rad S.A., Bio-Rad Services France, Bio-Rad Services UK Limited, Biotest - Businesses, Blackhawk Biosystems, Bridger Technologies Inc., Celsee, Ciphergen Biosystems - ProteinChip Systems Business, DiaMed (G.B.) Ltd, DiaMed (Schweiz) GmbH, DiaMed Benelux NV, DiaMed Diagnostika Deutschland GmbH, DiaMed France SA, DiaMed GmbH, DiaMed Holding AG, DiaMed Holding GmbH, DiaMed Latino-América S.A., DiaMed S.E.A. Limited, DiaMed Österreich GmbH, Distribudora de Analítica para la Medicina Ibérica S.A.U., Dropworks Inc., GnuBIO Inc., Helix Diagnostics, IMV Medical Information Division Inc., International Marketing Ventures Ltd., MJ GeneWorks, Propel Labs - Cell Sorting System Division, QuantaLife, Quantase Ltd., Raindance Technologies Limited, Raindance Techologies Inc., Research Specialties for Laboratories NV, Respiratory Diagnostics Inc., and Wuxi BioCanal Nano Technology Co. Ltd..

When was Bio-Rad Laboratories founded?

Bio-Rad Laboratories was founded in 1952.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is www.bio-rad.com.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at (510) 724-7000, via email at [email protected], or via fax at 510-741-5817.

This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.